Novartis, staring down tough market for M&A, leans toward $25B Sandoz spinoff: Bloomberg

For months, the industry has waited patiently as Novartis mulls the fate of its $25 billion generics arm. Now, it appears a spinoff could be in the cards.

Staring down a tough market for a potential private equity sale, Novartis is leaning toward spinning off its Sandoz division, Bloomberg reports, citing people close to the matter.